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Abstract: Antibiotics lead to increased susceptibility to colonization by pathogenic organisms,
with different effects on the host-microbiota relationship. Here, we show that metronidazole
treatment of specific pathogen-free (SPF) mice results in a significant increase of the bacterial phylum
Proteobacteria in fecal pellets. Furthermore, metronidazole in SPF mice decreases hind limb muscle
weight and results in smaller fibers in the tibialis anterior muscle. In the gastrocnemius muscle,
metronidazole causes upregulation of Hdac4, myogenin, MuRF1, and atrogin1, which are implicated
in skeletal muscle neurogenic atrophy. Metronidazole in SPF mice also upregulates skeletal muscle
FoxO3, described as involved in apoptosis and muscle regeneration. Of note, alteration of the gut
microbiota results in increased expression of the muscle core clock and effector genes Cry2, Ror-β,
and E4BP4. PPARγ and one of its important target genes, adiponectin, are also upregulated by
metronidazole. Metronidazole in germ-free (GF) mice increases the expression of other core clock
genes, such as Bmal1 and Per2, as well as the metabolic regulators FoxO1 and Pdk4, suggesting
a microbiota-independent pharmacologic effect. In conclusion, metronidazole in SPF mice results
in skeletal muscle atrophy and changes the expression of genes involved in the muscle peripheral
circadian rhythm machinery and metabolic regulation.
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1. Introduction
The mammalian gut hosts the most diverse population of microorganisms, including bacteria,
archaea, protozoa and fungi, and even viruses. The gut microbiota primarily provides protection
against pathogenic microorganisms and inflammation and helps with digestion and energy metabolism
by modulating various host signaling pathways [1]. The daily rhythmicity of the gut microbiota and its
metabolites modulates the host circadian rhythm [2]. Furthermore, gut dysbiosis and circadian rhythm
disruption are associated with metabolic syndrome and diseases such as obesity, type 2 diabetes,
and inflammatory bowel disease [3].
The gut microbiota composition is modulated by diet and antibiotics [4,5]. Antibiotics alter
microbiota composition and expression of microbial genes and derived metabolites such as bile acid
products and short-chain fatty acids, methylamines, and indoles [4,6]. Alteration of gut microbiota
composition may lead to deleterious effects on the host and colonization by antibiotic-resistant
pathogens [7]. Most of these findings come primarily from studies in animals exposed to various
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antibiotics, including metronidazole (1-(2-hydroxyethyl)-2-methyl-5-nitroimidazle) for a period of
4 weeks [8,9].
Furthermore, comparative analyses of specific pathogen-free (SPF) and germ-free (GF) mice are
often used to study the effects of microbiota on host metabolic and immune functions. Several studies
have demonstrated that GF mice are protected from diet-induced obesity, low-grade inflammation,
and glucose intolerance as compared to conventionally raised animals [10,11]. Furthermore, microbiota
transfer via fecal transplantation evokes modifications in body weight and insulin sensitivity in both
rodents and humans [4,10,12].
Metronidazole is in the nitroimidazole class of antimicrobial drugs, frequently used to treat
anaerobic, protozoal, and Helicobacter pylori infections [13]. It causes transient loss of colonization
resistance to pathogens [14]. When administered orally, metronidazole is absorbed almost completely
and distributed widely within the body. It is extensively metabolized by the liver, most likely
by the hepatic cytochrome P450 system, and its degradation products are excreted in urine and
feces [13]. Metronidazole is believed to enter the cerebrospinal fluid and the central nervous
system, which can cause neurotoxicity [13]. The effects in the central nervous system range
from seizures to metronidazole-induced encephalopathy and cerebellar syndrome. Recently,
antibiotic-associated encephalopathy was identified as a cause of delirium in patients receiving
antibiotics including metronidazole; however, peripheral neuropathy is the most common adverse
effect of metronidazole [15]. Of interest, many muscle functions, including energy metabolism,
myokine secretion, tissue homeostasis, and regeneration, are influenced by the skeletal muscle
peripheral clock and the clock-controlled genes [16–18], but the mechanism by which metronidazole
causes muscle weakness is not known. Because the microbiota participates in the control of the liver
peripheral clock [19], we hypothesized that, among other effects, metronidazole may also influence the
skeletal muscle peripheral clock.
Here we demonstrate that metronidazole causes changes in the expression of genes implicated in
the muscle peripheral clock machinery, metabolic regulators, and skeletal muscle neurogenic atrophy
that might be associated with peripheral neuropathy, the most commonly observed adverse side effect.
Metronidazole also causes protein degradation and thus acts as a double-edged sword in skeletal
muscle atrophy.
2. Results
2.1. Metronidazole Enhances Susceptibility to Colonization by Proteobacteria and Enrichment
of Erysipelotrichales
Consistent with other publications [8,9], we found that metronidazole treatment had a marginal
impact on the major bacterial phyla distribution in specific pathogen-free (SPF) mouse fecal pellets
analyzed by 16S rRNA gene sequencing. However, we found a slight but significant increase in
the susceptibility to colonization by Proteobacteria, especially Parasutterella AJ308395_s, compared to
nontreated control mice (Figure 1a). Furthermore, there was substantial enrichment of the bacterial
species Erysipelotrichales EF603943_s in the metronidazole-treated SPF mice when compared to the
nontreated control mice (Figure 1b).
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Figure 1. Metronidazole enhances susceptibility to colonization by Proteobacteria and enrichment
of Erysipelotrichales. 16s rRNA genes were sequenced from DNA extracted from the fecal pellets
of metronidazole (MET)-treated and nontreated control (CNTL) specific pathogen–free (SPF) mice.
(a) Percentage representation of the bacterial phyla distribution in fecal pellets of metronidazole-treated
and nontreated control SPF mice demonstrating increased susceptibility to colonization by Proteobacteria,
especially Parasutterella. N = 3 mice per group. Data are presented as means ± standard error of the
mean (SEM). Asterisks indicate statistically significant differences (*, p < 0.05; ns, nonsignificant with
student’s t test). (b) Gradient heatmap showing enrichment of the bacterial species Erysipelotrichales
in metronidazole-treated SPF mice as compared to nontreated controls. Relative abundance of the
bacterial species is color coded from minimum (red) to maximum (green). N = 3 mice per nontreated
control (CNTL1–3) and metronidazole-treated (MET1–3) groups.
2.2. Metronidazole Causes Skeletal Muscle Atrophy
The body weight of metronidazole-treated SPF mice was marginally but not significantly
reduced when compared to nontreated control mice (Figure 2a). However, the body weight
of metronidazole-treated germ-free (GF) mice was significantly reduced when compared to
nontreated control mice (Supplementary Figure S1a). The weight of the hind limb muscles of
metronidazole-treated SPF and GF mice was significantly reduced compared to nontreated control
mice, with the exception of the soleus in GF mice (Figure 2b and Supplementary Figure S1b).
Noticeably, the relative weight of the hind limb muscles of both SPF and GF mice did not display
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any significant differences between metronidazole-treated and nontreated control mice (data not
shown). However, histological examination of the tibialis anterior muscle at the mid-belly region of the
metronidazole-treated SPF mice revealed a significant decrease in larger myofibers and a concomitant
increase in smaller myofibers compared to nontreated control mice (Figure 2c). Taken together,
these data suggest that metronidazole treatment might lead to skeletal muscle atrophy.
Figure 2. Metronidazole causes reduced hind limb muscle weight and myofiber surface area.
(a) Metronidazole treatment of SPF mice resulted in a marginal, nonsignificant decrease in body
weight compared to nontreated controls. N = 5 mice per group. (b) Absolute hind limb muscle
weights of tibialis anterior (TA), extensor digitorum longus (EDL), gastrocnemius (GAS), soleus (SOL),
and quadriceps (QUAD) muscles of metronidazole-treated SPF mice compared to nontreated controls.
N = 5 mice per group. (c) Myofiber numbers according to myofiber surface area in the tibialis anterior in
metronidazole-treated and nontreated SPF mice. N = 3 mice per group. A thousand random myofibers
per mouse were counted across the mid-belly region of the tibialis anterior muscle cryosections.
Data presented as means ± SEM of 3000 myofibers per group (CNTL and MET). Asterisks indicate
statistically significant differences (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, nonsignificant with
student’s t test).
2.3. Metronidazole Causes Skeletal Muscle Neurogenic Atrophy
Denervation of skeletal muscle upregulates the histone deacetylases 4 and 5 (Hdac4/5), which then
repress dachshund family transcription factor 2 (Dach2), a negative regulator of myogenin. Increased
myogenin in turn upregulates the ubiquitin E3 ligases MuRF1 and atrogin1, causing skeletal muscle
atrophy [20]. Our analysis of gene expression in the mouse gastrocnemius revealed a significant
upregulation of skeletal muscle neurogenic atrophy markers, such as Hdac4, myogenin, MuRF1,
and atrogin1 expression, in metronidazole-treated SPF mice as compared to nontreated control
animals (Figure 3a). This effect was not observed in GF mice treated with metronidazole (Figure 3b).
The expression level of Hdac5 did not differ in SPF mice treated with and without metronidazole
(Supplementary Figure S2a). Dach2 expression level was reduced in metronidazole-treated SPF mice
when compared to nontreated control mice (Supplementary Figure S2a), but this trend did not reach
statistical significance (p = 0.063).
Forkhead box protein O3 (FoxO3) is a key transcription factor in protein breakdown, because it
modulates the activity of several actors in the ubiquitin–proteasome and autophagy–lysosomal
proteolytic pathways, including mitochondrial autophagy, also known as mitophagy [21,22]. Analysis
of mouse gastrocnemius revealed a significant increase in FoxO3 expression level in SPF mice treated
with metronidazole when compared to nontreated control mice, and the effect was not observed in GF
mice (Figure 3a,b). Furthermore, expression levels of the master regulator gene of myogenesis, MyoD,
the muscle mass–determining dominant-negative gene myostatin, and the autophagy marker genes
Mul1 and LC3-1 were unaffected by metronidazole treatment in SPF mice compared to nontreated
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control mice (Supplementary Figure S2b). Together, these data suggest that metronidazole causes
skeletal muscle atrophy through upregulation of myogenin and FoxO3.
Figure 3. Metronidazole causes changes in the expression of skeletal muscle atrophy genes. Real-time
quantitative PCR analysis of Hdac4, myogenin, MuRF1, atrogin1, and FoxO3 expression in gastrocnemius
of metronidazole-treated and nontreated (a) SPF and (b) GF mice. N = 5 mice per group. Data presented
as means ± SEM. Asterisks indicate statistically significant differences (*, p < 0.05; **, p < 0.01;
***, p < 0.001; ns, nonsignificant with student’s t test).
2.4. Metronidazole Is Involved in Skeletal Muscle Energy Metabolism
FoxO1 is a transcription factor that plays an important role in glucose metabolism by insulin
signaling. In skeletal muscle, FoxO1 increases expression of the mitochondrial pyruvate dehydrogenase
(acetyl-transferring) kinase isozyme 4 (Pdk4). This kinase phosphorylates subunits of pyruvate
dehydrogenase, which inhibits the activity of the enzyme. Inhibition of pyruvate dehydrogenase
decreases glucose use and increases fat metabolism, as during fasting [23,24]. We found that FoxO1
expression in gastrocnemius was significantly upregulated in SPF mice treated with metronidazole
compared to nontreated control mice (Figure 4a). Of note, metronidazole treatment of GF mice
triggered an opposite effect, with a significant reduction in expression level of FoxO1 compared to
nontreated control GF mice (Figure 4b). As a FoxO1 target gene, Pdk4 was upregulated in SPF mice
treated with metronidazole (not significantly, however, likely because of individual variation) and
significantly downregulated, together with FoxO1, in GF mice treated with metronidazole (Figure 4b).
Furthermore, there was no change in the expression levels of metabolic regulators such as Sirt1, Ampk,
Pgc-1α, PPARα, and PPARβ/δ in SPF mice treated with metronidazole compared to nontreated control
animals (Supplementary Figure S2c).
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Figure 4. Metronidazole affects the expression of skeletal muscle metabolism genes. Real-time quantitative
PCR analysis of FoxO1 and Pdk4 expression in gastrocnemius of metronidazole-treated and nontreated
(a) SPF and (b) GF mice. N = 5 mice per group. Data presented as means ± SEM. Asterisks indicate
statistically significant differences (*, p < 0.05; **, p < 0.01; ns, nonsignificant with student’s t test).
Together, these data suggest that, through its impact on FoxO1 and Pdk4 expression in SPF mice,
metronidazole could decrease glucose use in skeletal muscle through an effect on the microbiota,
which may participate with other effects in the observed skeletal muscle atrophy. In contrast, in the
skeletal muscle of GF mice, metronidazole had a microbiota-independent pharmacologic effect that
would promote glucose use.
2.5. Metronidazole Modulates Expression of Muscle Core Clock and Clock-Controlled Genes
Transcription of the clock gene Cry1 follows a circadian pattern in skeletal muscle [25],
and drugs such as prednisolone and ramipril can modulate skeletal muscle clock genes [26,27].
The gastrocnemius muscles of metronidazole-treated SPF mice displayed significant upregulation
of the core clock genes Per2 and Cry2 and a downregulation trend for Bmal1 when compared to
nontreated control mice (Figure 5a). Furthermore, Ror-β and E4BP4 were also significantly upregulated
after metronidazole treatment (Figure 5a). In contrast, the metronidazole-treated GF mice displayed
significant upregulation of Bmal1 and downregulation of Per2 as compared to the nontreated control GF
mice, again indicating a microbiota-independent effect opposite to that of the microbiota-dependent
effect in SPF mice (Figure 5b). Moreover, expression levels of Clock, Per1, Cry1, Ror-α and Ror-γ,
and Rev-erbα and Rev-erbβ did not differ significantly, and neither did those of clock-controlled genes
Dbp and Dec2 in the SPF mice treated with metronidazole (Supplementary Figure S2d).
Of note, PPARγ and its target gene adiponectin [28,29] were significantly upregulated in the SPF
mice treated with metronidazole (Figure 6a), an effect that was absent in metronidazole-treated GF
mice (Figure 6b). The expression of other factors important in metabolic regulation, such as Sirt1,
Ampk, Pgc-1α, PPARα, and PPARβ/δ, was not affected by metronidazole in SPF mice (Supplementary
Figure S2c). Together, these data show that in SPF mice, metronidazole affects some, but not all, genes
of the muscle clock and genes important in metabolism. In GF mice, metronidazole also affects clock
genes, but in a way opposite to that observed in SPF mice.
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Figure 5. Metronidazole alters skeletal muscle core clock and clock effector gene expression. Real-time
quantitative PCR analysis of Bmal1, Per2, Cry2, Ror-β, and E4BP4 expression in gastrocnemius of
metronidazole-treated and nontreated (a) SPF and (b) GF mice. N = 5 mice per group. Data presented
as means ± SEM. Asterisks indicate statistically significant differences (*, p < 0.05; ***, p < 0.001;
ns, nonsignificant with student’s t test).
Figure 6. Metronidazole modulates skeletal muscle adiponectin and PPARγ expression. Real-time
quantitative PCR analysis of PPARγ and adiponectin expression in gastrocnemius muscle of
metronidazole-treated and nontreated (a) SPF (a) and (b) GF mice. N = 5 mice per group. Data presented
as means ± SEM. Asterisks indicate statistically significant differences (*, p < 0.05; **, p < 0.01;
ns, nonsignificant with student’s t test).
2.6. Metronidazole Stimulates Expression of RNA Modification of N6-Methyladenosine Complex Genes
RNA modification is now recognized as playing a role in many important biological functions.
N6-methyladenosine (m6A) is an abundant modification of mRNA found in most eukaryotic RNAs [30].
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m6A can be incorporated by a methyltransferase complex, whose core is a methyltransferase such as
3 (METTL3)/METTL14 heterodimer, in which METTL3 provides the catalytic activity [31]. m6A is
recognized by YTH domain–containing proteins, which instruct different complexes to regulate RNA
signaling pathways [30]. It was recently found that m6A modification by METTL3 stabilizes MyoD
mRNA levels, thereby promoting skeletal muscle differentiation [32]. We therefore analyzed whether
metronidazole treatment changes the expression of genes for the methylation complex (Mettl3, Mettl14)
and for a YTH domain–recognition protein (Ythdf2), as well as that of the Fto gene, whose mRNA is
m6A methylated. We found that Mettl3 and Mettl14 showed increased expression in SPF mice treated
with metronidazole compared to nontreated controls (Figure 7a). This effect did not occur in GF mice
(Figure 7b). Also, we found no influence of metronidazole on Fto and Ythdf2 expression in SPF mice
(Supplementary Figure S2e). Collectively, these results demonstrate that metronidazole affects the
expression of genes involved in the RNA epigenetic modification machinery in skeletal muscle.
Figure 7. Metronidazole disrupts skeletal muscle RNA epigenetics. Real-time quantitative PCR
analysis of RNA m6A methyltransferases Mettl3 and Mettl14 expression in gastrocnemius muscle of
metronidazole-treated and nontreated (a) SPF and (b) GF mice. N = 5 mice per group. Data presented
as means ± SEM. Asterisks indicate statistically significant differences (*, p < 0.05; ns, nonsignificant
with student’s t test).
3. Discussion
The goal of this study was to characterize the effects of metronidazole on gut dysbiosis and muscle
health. We treated SPF and GF mice for 4 weeks with metronidazole in drinking water, similar to most
published studies involving antibiotic-treated mice [8,9]. In this study, all mice had ad libitum access to
food and water. We found that metronidazole caused gut dysbiosis with increased susceptibility to
colonization by Proteobacteria and enrichment of Erysipelotrichales in the treated SPF mice. A recent
report suggested that an increase in Parasutterella is associated with the development and progression
of irritable bowel syndrome (IBS) and chronic inflammation of the intestine [33]. Transferring aged gut
microbiota to young GF mice led to an increase in Proteobacteria involved in inflammatory aging and
inflammation of the small intestine [34]. Similarly, an increase in Erysipelotrichales has been associated
with inflammatory aging in older mice when compared to young mice [35]. Here we demonstrate
that this dysbiosis correlates with skeletal muscle atrophy with upregulation of Hdac4, myogenin,
and FoxO1/O3. It is possible that the increase in myogenin and FoxO1/O3 stimulated expression of the
E3 ubiquitin ligase genes MuRF1 and atrogin1 in the SPF mice treated with metronidazole. Therefore,
metronidazole might act as a double-edged sword in skeletal muscle atrophy, causing skeletal muscle
neurogenic atrophy through the upregulation of Hdac4 and myogenin and FoxO1/O3-mediated protein
degradation, resulting in the observed decrease in larger myofibers and consequent reduced hind
limb muscle weight. The effect of metronidazole on skeletal muscle neurogenic atrophy genes in the
SPF mice might explain the peripheral neuropathy observed in patients treated with metronidazole.
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We can speculate that the endotoxins produced by metronidazole-resistant proteobacteria might initiate
a tumor necrosis factor α–mediated inflammatory response, inhibiting Akt signaling and upregulating
the FoxO target genes MuRF1, atrogin1, and Pdk4 [36]. Moreover, the upregulation of Pdk4 in SPF mice
treated with metronidazole may inactivate the pyruvate dehydrogenase complex, which is rate-limiting
in muscle carbohydrate oxidation [37].
Furthermore, our results demonstrate a novel effect of metronidazole on genes involved in
the control of muscle circadian rhythm, energy metabolism, and RNA epigenetic modifications.
The gut microbiota and its daily rhythmicity of produced metabolites is reported to modulate host
circadian chromatin dynamics and transcriptome in intestine and liver [2]. It was proposed that
microbiota-generated signals are integrated by peripheral tissues to temporally organize genome-wide
transcription [2]. The mammalian circadian clock is a transcriptional and translational negative
feedback loop controlled by the core clock gene products Clock, Bmal1, Per1-3, and Cry1 and Cry2,
eventually regulating many biological processes [38]. The peripheral clocks in different organs
are coordinated by both the central master clock located in the suprachiasmatic nucleus of the
hypothalamus and zeitgebers such as light/dark, feeding/fasting, and rest/activity cycles [39].
The skeletal muscle peripheral clock and the clock-controlled genes have been implicated in energy
metabolism, myokine secretion, regeneration, and tissue homeostasis [16–18]. Our results show that
alteration of the microbiota composition with metronidazole in mice affects the host’s circadian rhythm
and metabolism of skeletal muscle. Expression levels of the core clock genes Per2 and Cry2 were
significantly upregulated in SPF mice treated with metronidazole, with a marginal downregulation in
Bmal1, suggesting that the host muscle peripheral clock genes are fine-tuned by the gut microbiota and
that dysbiosis affects this regulation process. In GF mice, we observed a microbiota-independent effect
of metronidazole on muscle, which interestingly contrasted with the effect seen with microbiota.
The clock-controlled genes Dbp and E4BP4 are critical in determining period lengths in rat-1
fibroblasts and act as positive and negative regulators of transcriptional activity, respectively [40].
Our results show an increase in Dbp expression level that was not significant because of the
large error limits among the metronidazole-treated SPF mice as compared to nontreated controls.
However, we also found a significant increase in expression level of E4BP4 in the SPF mice
treated with metronidazole, although the relevance of this observation remains to be elucidated.
Skeletal muscle–specific Bmal1 ablation in mice results in decreased glucose uptake and oxidation,
with increased Pdk4 expression causing a switch toward increased lipid metabolism in the muscles of
these mice [41]. Our results demonstrate a similar effect with metronidazole treatment in SPF mice,
indicating that these mice might undergo increased use of lipids for energy metabolism.
Both adiponectin and PPARγ were significantly upregulated in metronidazole-treated SPF mice.
We speculate that these effects might enhance fatty acid uptake and insulin sensitivity of skeletal
muscle. Furthermore, FoxO regulates adiponectin signaling through AdipoR, which is critical in
regulating lipid and glucose homeostasis and reducing oxidative stress [42].
Our results do not rule out the alternate possibility of changes in the gut mucosal barrier leading
to skeletal muscle atrophy because of poor digestion and nutrient absorption, which remains to
be investigated. Interestingly, malnutrition in children has been associated with an increase in
Proteobacteria [43]. In addition, a limitation of this study is that the tissue samples were harvested
in a single time window (zeitgeber time (ZT) 4–6). However, this time point was chosen based on
our finding that in GF mice, the strongest alteration in the expression of clock and clock effector
genes was observed at ZT6 [19]. Furthermore, it is likely that impaired peripheral nerve activity
might be accompanied by muscle incoordination, leading to altered expression of muscle clock genes.
Although further studies are required to elucidate the detailed molecular mechanism by which
the metronidazole-mediated alteration of gut microbiota composition modulates skeletal muscle
chronometabolism, the observed skeletal muscle atrophy is likely the result of disturbed expression of
both neurogenic atrophy genes and protein degradation genes.
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To conclude, metronidazole causes gut dysbiosis with increased susceptibility to colonization of
Proteobacteria and enrichment of Erysipelotrichales. Importantly, metronidazole causes skeletal muscle
atrophy and modulates muscle chronometabolism. These data support a role for the observed side
effect of metronidazole-mediated peripheral neuropathy in human patients.
4. Materials and Methods
4.1. Animals
Wild-type (WT; C57Bl/6J) mice were maintained at the SingHealth Experimental Medicine Centre
(SEMC), Singapore. The mice were inbred and housed in the SPF or GF facility of the SEMC. All mice
were housed in microisolator units of 5 males per cage and fed ad libitum with food and water.
The SPF WT mice were fed a standard irradiated chow diet and the GF mice a standard autoclaved
chow diet. All mice were maintained on a 12:12 h light and dark cycle. All mice were euthanized
using CO2 gas at ZT 4–6, where ZT0 is 07:30 and ZT12 is 19:30 at the start of the light and dark
periods, respectively. The animal work was approved and performed in accordance with the relevant
guidelines and regulations of the Institutional Animal Care and Use Committee (IACUC Reference
No. 2015/SHS/1133), SingHealth Experimental Medicine Centre, Singapore.
4.2. Antibiotic Metronidazole Treatment
Adult male WT SPF mice at 6–7 months of age and GF mice at 2 months of age were administered
1 g/L metronidazole (M-840-100; Gold Biotechnology, St. Louis, MO, USA) in drinking water for
4 weeks. Control WT SPF and GF mice received no metronidazole in drinking water. The drinking
water was changed twice weekly to compensate for the effects of the half-life of the drug.
4.3. Mouse Fecal Pellet and Tissue Harvest
Mouse fecal pellets were collected before euthanization, snap frozen in liquid nitrogen, and stored
at −80 ◦C until further analysis of the microbiota composition by 16s rRNA gene sequencing. The hind
limb tibialis anterior, extensor digitorum longus, gastrocnemius, soleus, and quadriceps muscles
were harvested from both legs, weighed, snap frozen in liquid nitrogen, and stored at −80 ◦C until
further analysis.
4.4. 16S rRNA Gene Sequencing of the Fecal Microbiota Population
Bacterial genomic DNA extraction, amplification, and 16S rRNA gene sequencing of the
metronidazole-treated SPF WT mice was carried out using a FastDNATM SPIN kit according to the
manufacturer’s protocol (MP Biomedical, Aurora, CT, USA) by Chunlab Inc., Seoul, South Korea [44].
Briefly, the DNA was first amplified using barcoded primers specific to the V1 and V3 regions of
the bacterial 16S rRNA genes. Sequences were then sorted out by their respective unique barcodes,
and low-quality reads were removed. Bacterial 16S rRNA gene sequencing of 1 µg of PCR amplified
product of each sample was done using the 454 GS FLX Titanium Sequencing System (Roche, Branford,
FL, USA). Sequence reads were identified using the EZBioCloud Genome Database. Fecal microbial
composition, diversity, and clustering were analyzed using the CLcommunity bioinformatics software
provided by Chunlab Inc., Seoul, Korea.
4.5. Histology
The left hind leg tibialis anterior muscle was OCT (optimum cutting temperature) embedded in
liquid nitrogen–cooled isopentane and stored at −80 ◦C. Serial transverse cryosections 10 µm thick
were obtained from the mid-belly region using a Leica cryostat machine. The sections were stained
with hematoxylin and eosin, cleared, and mounted in DPX (distyrene plasticiser xylene) mounting
compound. Representative pictures were taken with the brightfield 10× objective of a Leica microscope
and analyzed with Image J software (National Institutes of Health, Bethesda, MD, USA).
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4.6. RNA Isolation and RT-qPCR Analysis
Total RNA was isolated from the gastrocnemius muscle using Trizol reagent and a PureLink®
RNA Mini Kit (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions.
cDNA was synthesized from 1 µg of RNA using iScript Reverse Transcription Supermix (Bio-Rad,
Hercules, CA, USA). Real-time quantitative PCR was performed with KAPA SYBR FAST qPCR kits
(KAPA Biosystems, Wilmington, MA, USA). The oligonucleotides (Supplementary Table S1) were
ordered from Integrated DNA Technologies, Singapore. The relative mRNA levels were quantified
using the ABI StepOne Plus RT-qPCR System in accordance with KAPA Biosystem cycling conditions.
All amplified PCR products were calculated based on comparative delta-Ct method and normalized to
endogenous glyceraldehyde-3-phosphate dehydrogenase mRNA levels.
4.7. Statistical Analysis
Statistical differences between groups were determined using unpaired two-tailed student’s
t-tests, and the results were considered significant at p < 0.05 (*), p < 0.01 (**), or p < 0.001 (***). Data are
expressed as mean ± standard error of the mean (SEM).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/8/
2418/s1.
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Abbreviations
Clock Circadian locomotor output cycles kaput
Bmal1 Brain and muscle ARNT-like 1
Per Period
Cry Cryptochrome
Ror RAR-related orphan receptor
E4BP4 E4 promotor binding protein 4
Dbp D site binding protein
Akt Akt serine/threonine kinase
MuRF1 Muscle RING-finger protein 1
MyoD Myogenic differentiation
Mul1 Mitochondrial E3 ubiquitin protein ligase 1
LC3-1 MAF1 light chain 3–like protein 1
Ppar Peroxisome proliferator activated receptor
Pgc-1α Ppar gamma coactivator 1 alpha
Sirt1 Sirtuin 1
AMPK AMP-activated protein kinase
AdipoR Adiponectin receptor
Fto Fat and obesity–associated protein
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